Approximately 40-50% of the cutaneous melanomas harbor oncogenic driver mutations at V600 codon in the serine-threonine kinase BRAF and this mutation induce constitutive activation of the MAPK signaling pathway [19–21]. Here, MARK2 is linked to cutaneous melanoma.